Valneva’s Pipeline Progress Offers a Counterweight to Slumping Travel Vaccine Sales

Valneva's Q1 revenue slid to €30.9M, but a 70%+ efficacy readout for its Lyme vaccine and Brazil's green light for its chikungunya shot reshape the mid-term outlook. Shigella data due mid-2026.

The French biotech group Valneva is living a split narrative in 2026. On one side, quarterly revenues have shrunk sharply and the stock trades more than 30% below where it started the year. On the other, a string of clinical and regulatory wins – from a 70%+ efficacy readout for its Lyme disease vaccine candidate to a manufacturing green light in Brazil – is beginning to reshape the company’s medium-term outlook.

Revenue Slide and Cash Position

Valneva’s total first?quarter revenue came in at €30.9?million, down from €49.2?million in the same period a year earlier. The drop was driven by a planned wind?down of third?party product sales and a shift in delivery schedules to the US market, compounded by weaker demand for travel vaccines in several key regions owing to geopolitical factors. Product revenue alone stood at €30.5?million.

At the end of March the company held €105.3?million in cash. That figure does not yet include proceeds from a recent capital increase, which will provide additional runway as Valneva pushes its late?stage pipeline toward regulatory decisions.

Lyme Vaccine Hits Key Milestone

The strongest news flow of the quarter came from the Lyme disease programme, developed jointly with Pfizer. In March, topline data from the pivotal Phase?3 VALOR study showed that the hexavalent candidate LB6V achieved a vaccine efficacy of more than 70% in individuals aged five years and older. No safety concerns were identified during the analysis. Pfizer is now preparing the necessary regulatory filings, and VLA15 – the only Lyme vaccine programme in late?stage clinical development – is on track for submissions.

Brazil Becomes a Strategic Pivot for Chikungunya

While Valneva voluntarily withdrew its US approval and study applications for the one?shot chikungunya vaccine IXCHIQ in January 2026, the company has found a strong alternative in Brazil. In early May, the Brazilian health authority ANVISA granted the Instituto Butantan permission to produce a local version of the vaccine for adults aged 18 to 59, opening the door for integration into the country’s public health system.

This follows an ongoing pilot vaccination campaign that began in February, under which more than 30,000 adults have already been immunised. The Brazilian market is now emerging as a critical outlet for Valneva’s chikungunya franchise.

Shigella Data on the Horizon

The next major pipeline catalyst is S4V2, Valneva’s tetravalent vaccine candidate for shigellosis – one of the deadliest diarrhoeal diseases globally. Two Phase?2 studies are running in parallel: one in infants and a human?challenge study. First results are expected around mid?2026.

If both data sets prove positive, Valneva will continue the development itself. The programme already carries US FDA Fast?Track designation, awarded in October 2024, and the annual market opportunity is estimated at more than $500?million. No multivalent Shigella vaccine is currently approved outside Russia and China.

Stock Under Pressure Despite Catalysts

The market has so far been unimpressed. Valneva’s shares closed at €2.62 on Thursday, up 2.95% on the day, but the year?to?date loss stands at 31.87%. The stock is trading nearly 35% below its 200?day moving average, and intraday volatility remains high.

All the same, the coming months are dense with milestones. Pfizer is moving forward with regulatory filings for the Lyme vaccine, Valneva will release the S4V2 Phase?2 data, and real?world evidence from Brazil’s IXCHIQ campaign is accumulating. For now, the company’s narrative is gradually shifting from falling travel?vaccine revenues to the resilience of its development pipeline.